In addition, colitis occurred much earlier in CTLA-4 inhibitor-containing regimens than in non-CTLA-4 inhibitor-containing regimens (median duration: 28 days vs. 157 days, P=0.019; median immunotherapy cycles: 2 cycles vs. 8 cycles, P=0.015). This evidence concerns the gene CTLA4 and colitis.